Candriam S.C.A. Bio Atla, Inc. Transaction History

Candriam S.C.A.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$2.3 - $8.25 $552,000 - $1.98 Million	-240,000 Reduced 13.29%	1,565,406 $4.2 Million
Q4 2022 Feb 13, 2023	SELL	$6.29 - $11.01 $660,450 - $1.16 Million	-105,000 Reduced 5.5%	1,805,406 $14.9 Million
Q3 2022 Nov 10, 2022	BUY	$2.94 - $11.87 $4.49 Million - $18.1 Million	1,528,367 Added 400.06%	1,910,406 $14.7 Million
Q1 2022 May 13, 2022	SELL	$4.38 - $18.78 $98,974 - $424,371	-22,597 Reduced 5.58%	382,039 $1.91 Million
Q3 2021 Nov 09, 2021	BUY	$29.44 - $43.74 $8.1 Million - $12 Million	275,038 Added 212.22%	404,636 $11.9 Million
Q2 2021 Jul 20, 2021	BUY	$38.07 - $56.17 $4.93 Million - $7.28 Million	129,598 New	129,598 $5.49 Million

17.3M

500

33.5K

Ticker BCAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,304,100
Market Cap $62.4M
Description
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

Stay updated on Candriam S.C.A. with notifications on news.